Compare LRE & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRE | SER |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Japan | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 19.4M |
| IPO Year | 2022 | N/A |
| Metric | LRE | SER |
|---|---|---|
| Price | $1.29 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 7.3K | ★ 40.6K |
| Earning Date | 07-30-2015 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $1.22 |
| 52 Week High | $2.86 | $7.92 |
| Indicator | LRE | SER |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 50.97 |
| Support Level | $1.20 | $1.74 |
| Resistance Level | $1.45 | $2.25 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 70.87 | 35.04 |
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.